Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 170, Issue -, Pages 142-199Publisher
ELSEVIER
DOI: 10.1016/j.addr.2021.01.005
Keywords
Atherosclerosis; Nanomaterials; Therapeutic delivery system; Imaging contrast agents; Theranostic agents; Clinical use
Categories
Funding
- National Institutes of Health [1R01HL150887, 1R01HL125391]
- American Heart Association [18POST34080260, 20PRE35210599]
- National Research Foundation of Korea (NRF) - Korea government (MSIT) [2020R1A2C3003784, 2020M3A9I4038454]
- National Research Foundation of Korea [2020M3A9I4038454, 2020R1A2C3003784] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
Atherosclerosis is a chronic inflammatory disease caused by lipid accumulation in arteries, leading to narrowing and thrombosis. Nanomaterials have been developed for improving the diagnosis and treatment of atherosclerosis, showing promise in both preclinical and clinical stages.
Atherosclerosis is a chronic inflammatory disease driven by lipid accumulation in arteries, leading to narrowing and thrombosis. It affects the heart, brain, and peripheral vessels and is the leading cause of mortality in the United States. Researchers have strived to design nanomaterials of various functions, ranging from noninvasive imaging contrast agents, targeted therapeutic delivery systems to multifunctional nanoagents able to target, diagnose, and treat atherosclerosis. Therefore, this review aims to summarize recent progress (2017 now) in the development of nanomaterials and their applications to improve atherosclerosis diagnosis and therapy during the preclinical and clinical stages of the disease. (c) 2021 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
